The Access NT-proBNP Feasibility Study[1]

Key Facts

- A prospective study to evaluate the clinical performance of Access NT-proBNP for the diagnosis of acute heart failure
- 490 medically complex patients enrolled with 41% adjudicated with acute heart failure
- A multicenter trial conducted across 9 hospital-associated Emergency Departments in the United States

High diagnostic accuracy validated for acute heart failure at ESC and HFSA society preferred cut points[2]

Age-independent rule-out cut point of 300 ng/L

- 96% sensitivity (95% CI: 92 to 98%)
- 95% negative predictive value (95% CI: 91 to 98%)

Age-stratified diagnostic cut points

450 ng/L, <50 years

- 84% sensitivity (95% CI: 73 to 91%)
- 81% specificity (95% CI: 72 to 87%)
- 72% positive predictive value (95% CI: 61 to 81%)

900 ng/L, 50-75 years

- 90% sensitivity (95% CI: 81 to 95%)
- 70% specificity (95% CI: 62 to 77%)
- 62% positive predictive value (95% CI: 52 to 71%)

1800 ng/L, >75 years

- 87% sensitivity (95% CI: 81 to 95%)
- 61% specificity (95% CI: 62 to 77%)
- 74% positive predictive value (95% CI: 64 to 82%)



The novel Access NT-proBNP assay showed similar performance to commercially cleared methods in diagnosing acute heart failure, with performance characteristic typical of natriuretic peptide assay

Conclusion

- The novel Beckman Access NT-proBNP assay demonstrated high clinical accuracy in supporting the timely identification of acute heart failure in the undifferentiated dyspneic patients during initial presentation in the Emergency Departments.
- The performance of the Access NT-proBNP assay achieved similar high sensitivty and specificty compared to validated commercial NT-proBNP assays at clinical society preferred cut points.

1. Jessica Guidi, Brandon Allen, Gary Headden, Nicole Winden, Dileepa Alahapperuma, Robert H Christenson, W Franklin Peacock, James L Januzzi. A novel NT-proBNP assay for heart failure diagnosis: A prospective, multicenter clinical trial, Clinica Chimica Acta (2025), doi: https://doi.org/10.1016/j.cca.2025.120249

2. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Eur J Heart Fail (2023). doi: 10.1002/ejhf.2848. Epub 2023 Apr 2

For Beckman Coulter's worldwide office locations and phone numbers, please visit **www.beckmancoulter.com/contact**

2025-14307

danaher